FIG E1. Individual antibody responses ($\ln[K_v]$) to phiX174 immunization over time in rituximab-treated subjects.

TABLE E1. Baseline clinical characteristics (subjects who received 4 full infusions of rituximab or ≥3 placebo infusions)

	Rituximab group (n = 46)	Control group (n = 29)	Overall
Age (y), mean ± SD	20.1 ± 8.9	17.4 ± 8.0	19.1 ± 8.6
Median age (y), min-max	18 (8-40)	14 (9-38)	16 (8-40)
Male sex, no. (%)	29 (63)	17 (59)	46 (61)
White race, no. (%)	44 (96)	28 (97)	72 (96)
Non-Hispanic, no. (%)	43 (93)	26 (90)	69 (92)
No. of positive autoantibodies (%)*			
1	9 (20)	3 (10)	12 (16)
2	13 (28)	7 (24)	20 (27)
3	13 (28)	8 (28)	21 (28)
4	11 (24)	11 (38)	22 (29)
Time since diagnosis (d) at baseline	80 ± 23	84 ± 19	81 ± 22
Median (d), range	81 (37-137)	91 (34-109)	85 (34-137)

*Four autoantibodies associated with T1D were tested: mIAA, GAD65-Ab, ICA512-Ab, and ICA.

TABLE E2. Actual numbers for the measurements in Table II

Days after immunization	Primary response			Secondary response		
	Rituximab group	Control group	Healthy control subjects	Rituximab group	Control group	Healthy control subjects
7	20	15	52	18	15	52
14	20	15	50	20	13	51
28	19	15	52	20	13	51

Days after immunization	Tertiary response			Quaternary response		
	Rituximab group	Control group	Healthy control subjects	Rituximab group	Control group	Healthy control subjects
7	13	14	17	11	13	0
14	16	15	18	12	15	0
28	16	14	19	13	15	0